Studies of who receives GLP-1 treatment examine access across age groups. This study instead compared health outcomes for people aged 80 and older who started one of two diabetes treatments [1].
What the study compared
Researchers matched 11,464 pairs of people with type 2 diabetes who started either a GLP-1 receptor agonist or a DPP-4 inhibitor. Follow-up extended up to five years [1].
Death from any cause was recorded in 14.5% of GLP-1 users and 19.1% of DPP-4 users. The estimated hazard ratio was 0.82 (95% CI 0.77 to 0.88). The hazard ratios for major cardiovascular and major kidney events were each 0.86.
How to read the safety findings
Research on fractures in another GLP-1 cohort examines a different population. This study found no statistically clear difference in fracture or heart failure hazards [1].
Matching accounted for measured characteristics. Unmeasured factors, such as functional status or the reasons one treatment was chosen, could still affect the results. The study applies most directly to older adults starting treatment for type 2 diabetes.